scholarly journals Adjuvant Intravesical Chemotherapy in the Management of Superficial Transitional Cell Carcinoma of Urinary Bladder Following Transurethral Resection of Bladder Tumor- Result of Single Dose and Multiple doses of Mitomycin C

2020 ◽  
Vol 23 (1) ◽  
pp. 62-66
Author(s):  
Shahriar Md Kabir Hasan ◽  
Kazi Rafiqul Abedin ◽  
Md Shawkat Alam ◽  
Anup Roy Chowdhury ◽  
Md Moynul Hoque Chowdhury ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Single Dose ◽  
Urinary Bladder ◽  
Transitional Cell Carcinoma ◽  
Mitomycin C ◽  
Dose Group ◽  
Transitional Cell ◽  
Group A ◽  
Group B

Background: Bladder cancer is the second most common cancer of the genitourinary tract. Mitomycin C has been commonly used in a perioperative fashion delivered intravesically immediately after TURBT Objective: To compare the results of post TURBT immediate single dose and multidose regimen of Mitomycin C therapy in the management of superficial transitional cell carcinoma of the urinary bladder. Method: The present prospective and comparative interventional study was conducted in the Department of Urology, National Institute of Kidney Diseases and Urology, Sher-E-Bangla Nagar, Dhaka from January 2015 to December 2016. Patients of superficial bladder cancer (tumor size ≤3 cm, number ≤3, grade I, II) were randomly included in the 2 groups. The sample size was seventy four (74). Thirty (30) patients were in each group and fourteen (14) were excluded from the study. In MMC single dose group (Group A), single dose of MMC 40mg/ 40ml was started immediately within 24 hours of TURBT. In MMC multi-dose group (Group B) 1st instillation of chemotherapy was started immediately within 24 hours of TURBT and additional instillation (5 instillations) were given as OPD basis and was continued weekly for 5 weeks. Follow-up was done on 3rd, 6th, 12th month of initial TURBT. Results: In this study mean age was 61.8±13.7 years in group A and 62.7±13.6 years in group B. Male was found 25 (83.3%) in group A and 26 (86.7%) in group B. Female was found 5 (16.7%) in group A and 4 (13.3%) in group B. Mean size of the tumor was found 2.13±0.78 cm in group A and 2.05±0.84 cm in group B. Mean number of tumor was found 1.8±0.8 in group A and 1.9±0.7 in group B. Tumor grade I was found 23 (76.7%) in group A and 25 (83.3%) in group B. Tumor status Ta of superficial bladder was found 25 (83.3%) in group A and 26 (86.7%) group B. Tumor status T1 of superficial bladder was found 5(16.7%) in group A and 4 (13.3%) group B. Five (16.7%) patients was found recurred in group A and 4 (13.3%) in group B at 6th month follow up. At 12th month follow up, 6 (20.0%) patients was found recurred in group A and 5 (16.7%) in group B. Side effect was found in 2 (6.7%) patients in group B and not found in group A. Conclusion: MMC single dose was similar to MMC multi-dose regimen with insignificant difference among the two. Bangladesh Journal of Urology, Vol. 23, No. 1, January 2020 p.62-66

scholarly journals A Comparative Study Between Single Dose & Multiple Doses of Mitomycin-C in the Management of Transitional Cell Carcinoma of Urinary Bladder

2020 ◽  
Vol 20 (2) ◽  
pp. 74-77
Author(s):  
Nazrul Islam Mridha ◽  
Sudip Das Gupta ◽  
Mohammad Mahfuzur Rahman ◽  
Man Wahid ◽  
Sanjib Kumar Roy
Keyword(s):  
Single Dose ◽  
Urinary Bladder ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mitomycin C ◽  
Dose Regimen ◽  
Transitional Cell ◽  
Intravesical Instillation ◽  
Group A ◽  
Group B

Objectives: To find out the efficacy of post TURBT immediate single dose adjuvant intravesical Mitomycin C therapy in comparison with multi-dose regimen of Mitomycin C therapy in the management of superficial transitional cell carcinoma of the urinary bladder. Methods: Total 76 patients of bladder mass were included in the study who had undergone transurethral resection followed by immediate single instillation of Mitomycin C. After availability of histopathological examination report of resected tumor, those fulfill the selection criteria were randomized into two groups. One group (Group A) was the odd numbers of the patients who already received immediate single intravesical instillation of Mitomycin C and another group (Group B) even number of the patients who received single dose of intravesical instillation of Mitomycin C immediately with additional 5 instillations (1 week interval for 5 weeks) and in whom prospective follow-up could be completed within next 12 months Results: The effect of single intravesical instillation of 40 mg of Mitomycin C (Group A) within 24 hours of TURBT with that of multiple doses (six doses) of Mitomycin C (Group B) in similar dose was insignificant. Conclusion: The efficacy of MMC single dose was similar to MMC multi-dose regimen with insignificant difference of side effect among the two groups (0% versus 6.25%). Bangladesh Journal of Urology, Vol. 20, No. 2, July 2017 p.74-77

scholarly journals Recurrence rate of superficial bladder cancer with intravesical BCG and mitomycin.

2021 ◽  
Vol 28 (06) ◽  
pp. 854-860
Author(s):  
Khalid Hussain ◽  
Muhammad Asif ◽  
Farooq Malik ◽  
Munazza Yasmeen ◽  
Maria Tariq ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Recurrence Rate ◽  
Superficial Bladder Cancer ◽  
Controlled Trial ◽  
Transitional Cell ◽  
Female Ratio ◽  
Intravesical Bcg ◽  
Group A ◽  
Group B

Objective: To compare the recurrence rate of superficial transitional cell carcinoma of urinary bladder using intravesical BCG and Mitomycin-C. Study Design: Randomized Controlled Trial. Setting: Urology Department, Teaching DHQ Hospital, Gujranwala. Period: November 2018, to Sep, 2019. Material & Methods: Was carried out on total 270 patients, admitted with suspicion of urothelial tumors. They were grouped in Group A and B, comprising 135 in each group. Group A received BCG and Group B received Mtiomycin-C intravesically following TUR-BT. Results: Out of 270 patients male to female ratio was 3:1. Age range of patients was between 30 to 70 years with mean of 50.0± 13.1 and 552.3 ± 12.9 years in Group A and B respectively. Recurrence was noted in 05.38% and 15.38% patients in Group A and B respectively. Regarding side effects pyrexia was associated with BCG in 27.40% patients which were self-limited in 26.66% cases however required anti-tuberculosis therapy for six months in 0.74%. Whereas only 06.67% patients receiving Mitomycin had pyrexia. Dysuria occurred in 74% and frequency in 68% patients who received BCG. Whereas Dysuria occurred in 20% and frequency in 36.29% patients who received Mitomycin-C. However genital skin rash was more common (08.14%) in Mitomycin group than BCG. Conclusion: Keeping in mind less recurrence rate and bearable toxicity, it is concluded that BCG is superior to Mitomycin. This study suggests long term follow up is required to establish recurrence in the management of superficial bladder cancer.

scholarly journals To Compare Frequency of Tumour Recurrence in Low Risk Transitional Cell Carcinoma of Bladder Between Single Dose Mitomycin C Instillation and Control Group

2020 ◽  
Vol 10 (2) ◽  
Author(s):  
Sanaullah . ◽  
Mumtaz Ali ◽  
Nizamuddin . ◽  
Fazal Elahi ◽  
Amanullah . ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Recurrence Rate ◽  
Transitional Cell ◽  
Low Risk ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Group A ◽  
Muscle Invasive ◽  
Group B

Background: Many regimes of intravesical therapy have been tried in attempt to reduce the recurrence rate of non muscle invasive bladder cancer, these generally require frequent attendance for instillation. Multiple non-comparative studies have demonstrated the favourable outcomes of the immediate treatment by instillation of mitomycin C after transurethral resection of bladder tumor (TURBT) in cases of non-muscle invasive Transitional Cell Carcinoma.Objective: To compare frequency of tumour recurrence in low risk transitional cell carcinoma of bladder between single dose Mitomycin C instillation and control group.Material and Methods: This study was conducted at urology departmentsaidu teaching hospital and Nawaz sharif kidney center swat. Study Design Quasi Experimental.Study Duration was (From: Feb 2018 to February 2019). Total 62 patients fulfilling the inclusion criteria were selected. Patient were divided between group A and B according to Non probability purposive sampling. TURBT was done in all patients. In those assigned to group A Mitomycin C 40mg was instilled through foleys catheter and clamped within 12 hrs of resection once haematuria has cleared. Mitomycin C was retained for 2 hrs and then foleys catheter was removed.Results: Mean age of patients in Group-A and in Group-B was 54.90±11.48 and 60.03±13.58 years respectively. In Group-A 1(3.2%) and in Group-B 9(29%) patients had recurrence after 3 months follow up time period. Recurrence rate of Group-B was significantly higher. i.e. (p-value=0.006).Conclusion: Results of this study showed the superiority of mitomycin C in patients with low risk non muscle invasive bladder cancer in terms of significantly lower recurrence rate as compared to that of control group. So, it can be said that single mitomycin C instillation significantly decrease recurrence in patients with low risk non muscle invasive bladder cancer.

Carcinoma of the unrivaled bilharzial urinary bladder of Egyptians: Expanding radiotherapy and decline of obligate cystectomy—Historic perspective and a demonstration study of 34 patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15571-e15571
Author(s):  
Gamal Moustafa Saied ◽  
Karim G Moustafa
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Cell Carcinoma ◽  
Transurethral Resection ◽  
Transitional Cell ◽  
Treatment Modalities ◽  
Clinicopathological Findings ◽  
Egyptian Patients ◽  
Group A ◽  
Group B

e15571 Background: The objective is to validate the new clinicopathological features involving carcinoma of the unrivaled urinary bladder of Egyptian patients, alongside studying their reflection on management. Methods: Timely contributions of leading Egyptian experts in bladder cancer in the last 4 decades were reviewed. Additionally, 34 patients were studied in 2 subsets based on planned treatment modality: group A (12 cases) treated by cystectomy and group B (22 cases) treated by transurethral resection plus stipulated radiotherapy. Treatment results were evaluated. Results: An overview of studies published in the last 4 decades is given, demonstrating a striking change in the characteristic features of bladder carcinoma in this country, more obvious in 2007 and after. Present work revealed 44.1% of patients had their tumor erupting in a bilharzial bladder where walls demonstrated classical cystoscopic features of the disease. Histologically 86.7 % of them were squamous cell carcinoma. Almost 60% of patients had had their tumors in a non-bilharzial bladder, 94.7% of them were transitional cell carcinoma. Thirteen out of 15 patients in group A were treated by cystectomy carrying 7.7 % perioperative mortality, whereas 11 out of 12 patients in group B received radiotherapy preceded by transurethral resection. Distribution of clinicopathological findings and treatment modalities is tabulated. Conclusions: Bladder cancer in Egyptian patients has lost its weird features imposed by bilharzial cystitis. It is shifting towards alien types making it suitable for organ preserving management.

scholarly journals SUPERFICIAL BLADDER TUMOR;

2013 ◽  
Vol 20 (06) ◽  
pp. 909-915
Author(s):  
AMJAD ALI SIDDIQUI ◽  
JAMSHED RAHIM ◽  
ATHAR MAHMOOD ◽  
Jamil Rahim
Keyword(s):  
Bladder Cancer ◽  
Single Dose ◽  
Mitomycin C ◽  
Bladder Tumor ◽  
Superficial Bladder Cancer ◽  
Control Group ◽  
Significant Difference ◽  
Superficial Bladder Tumor ◽  
Group A ◽  
Group B

Introduction: Bladder cancer is the second most common urologic cancer. Approximately 90% are transitional cellcarcinoma among which superficial bladder cancer constitutes about 50-70%. It is usually treated by transurethral resection withadjuvant intravesical instillations of chemotherapy or immunotherapy. Primary problems in superficial bladder cancers are its tendency torecur, about 50-80%, following surgical ablation alone, with progression to muscle invasive disease in 20-25% cases. Intravesicalchemotherapy appears to have major impact on decreasing chances of recurrence of superficial bladder cancer. Objective: To determinethe efficacy of single dose perioperative intravesical mitomycin C in reducing recurrence of superficial bladder tumor. Study Design:Comparative study. Settings: Department of Urology Shaikh Zayed Hospital Lahore. Duration of Study: One year.13-04-2009 to 13-04-2010. Methodology: Patients were divided into two groups randomly by using random numbers i.e. 40 patients in group A and 40 patientsin group B. Group A (40 patients) of bladder tumor received post TURBT single dose Mitomycin-C 40 mg/40ml N/Saline intravesically andGroup B (40 patients) was control group i.e. TURBT alone without Mitomycin-C. Results: The recurrence at first year follow up in bothgroups were showed a significant difference (p<0.05) as shown in Table No V: There were only 10% recurrence in Group A i.e. patientswho had intravesical Mitomycin –C as compared to 55% recurrence in Group B, who did not received postoperative intravesicalMitomycin–C. Conclusions: It is concluded that one perioperative (within 6 hours of TURBT) intravesical instillation of chemotherapysignificantly decreases the risk of recurrence after TURBT in patients with stage Ta T1, single and multiple papillary bladder cancer in lowrisk as well as high risk tumors. One immediate instillation after TUR reduces the recurrence.

scholarly journals Mitomycin c in the treatment of metastatic transitional cell carcinoma of urinary bladder

Cancer ◽  
1973 ◽  
Vol 31 (5) ◽  
pp. 1150-1153 ◽  
Author(s):  
K. Early ◽  
E. G. Elias ◽  
A. Mittelman ◽  
D. Albert ◽  
G. P. Murphy
Keyword(s):  
Urinary Bladder ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mitomycin C ◽  
Transitional Cell

Chemioprofilassi endovescicale del carcinoma uroteliale superficiale. Studio su mitomicina ed epirubicina in differenti dosaggi

1994 ◽  
Vol 61 (1_suppl) ◽  
pp. 25-29
Author(s):  
M. Pastorello ◽  
A. Molon ◽  
M. Poluzzi ◽  
F. Venturi ◽  
I. Siggillino
Keyword(s):  
Recurrence Rate ◽  
Tumour Progression ◽  
Transitional Cell ◽  
Chemotherapeutic Agents ◽  
High Recurrence Rate ◽  
Multiple Neoplasms ◽  
Group A ◽  
Group B ◽  
Histological Confirmation

Superficial transitional cell carcinomas (TCC) of the bladder have a high recurrence rate and a potential for progressive disease. The intravesical use of chemotherapeutic agents to prevent recurrences has achieved varying success. We report our experience in the prevention of superficial TCC recurrences using topical Mitomycin C or Epirubicin (in two different doses). After complete transurethral resection (TURB) and histological confirmation of stage pTa or pT1 disease, 80 patients were assigned to group A (Mitomycin 40 mg in 40 ml); 80 pts to group B (Epirubicin 50 mg in 50 ml); 40 pts were enrolled in group C (Epirubicin 80 mg in 50 ml saline). Median follow-up is 43.4 months for group A, 42.1 months for gr. B, 21.1 months for gr. C. 183 pts could be evaluated. Results: 28/74 pts had recurrences in gr. A, 26/73 in gr. B, 11/36 in gr. C; the recurrence index/100 pt-months is 1.21 in gr. A, 1.23 in gr. B, 2.10 in gr. C. Tumour progression was registered in 13/74 pts in gr. A, in 11/73 in gr. B, in 5/36 in gr. C. pT1-tumours showed a recurrence rate of 69% (average of the three groups) versus 13% of pTa-tumours; a very high recurrence rate was also observed in multiple neoplasms.

Adjuvant Intravesical Chemotherapy in Patients with Primary T1 G3 Transitional Cell Carcinoma of the Bladder

1993 ◽  
Vol 60 (4) ◽  
pp. 345-348
Author(s):  
V. Serretta ◽  
S. Piazza ◽  
C. Pavone ◽  
G. Corselli ◽  
B. Piazza ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
Invasive Disease ◽  
Intravesical Chemotherapy ◽  
Carcinoma Of The Bladder ◽  
Bladder Tumours

The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document